Trial · NCT06485544
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
NCT06485544, Phase 2, Recruiting, Tang-Du Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial. Trials, record NCT06485544. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06485544
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
- NCT number
- NCT06485544
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 104 participants, estimated
- Lead sponsor
- Tang-Du Hospital
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Adebrelimab + Etoposide + Platinum-based Therapy, Etoposide + Platinum-based Therapy
- First posted
- 2024-07-03
- Last updated
- 2024-07-03
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological complete response rate(pCR) | 7 days after surgery. | Pathologic complete response (pCR), defined as the absence of tumor cells in all specimens (ypT0N0) . |
| Secondary | Event-free survival (EFS) | Long term follow-up will continue until preoperative progression, postoperative recurrence, or death from any cause at least two years. | The length of time after primary treatment for a cancer ends that the patient remains free of certain complicationsor events that the treatment was intended toprevent or delay. |
| Secondary | Major pathologic response (MPR) | 7 days after surgery. | MPR is defned as less than 10% residual viable tumor after neoadjuvant therapy. |
| Secondary | Objective response rate (ORR) | 7 days before surgery | Per Response Evaluation Criteria in Solid Tumorsersion 1.1(REClST 1.1) using Investigator assessments, is defneas the number (%) of patients with responseof Complete Response or Partial Response. |
| Secondary | Disease-free survival(DFS) | Long term follow-up will continue until the death of the subiect or the end of the studv. at least two years | The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06485544
GET https://conductscience.org/api/trials/v1/NCT06485544/registered